The auditors themselves seem to contest the valuation of biological assets, knocking back the assumptions (to a still somewhat optimistic level in my view!) and effectively knocking $15m off the value of biological assets.
That takes the profit of $5.5m back to a loss of $9.4m! Amazingly, it seems the accounts remain unaltered with just the auditors note on valuation impact to provide a truer picture.
The auditors are clearly also concerned about cashflow with the "going concern" comments.
What a disaster!
APB Price at posting:
4.4¢ Sentiment: Sell Disclosure: Not Held